Brighton Jones’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-19,491
Closed -$350K – 1509
2026
Q2
$350K Sell
19,491
-13,502
-41% -$255K 0.01% 969
2026
Q1
$718K Buy
+32,993
New +$639K 0.02% 559
2018
Q3
– Sell
-4,685
Closed -$619K – 312
2018
Q2
$619K Buy
4,685
+8
+0.2% +$754 0.08% 145
2018
Q1
$347K Buy
4,677
+16
+0.3% +$1.07K 0.05% 196
2017
Q4
$259K Hold
4,661
– – 0.03% 238
2017
Q3
$211K Buy
+4,661
New +$186K 0.03% 264

Other funds holding SRPT

Brighton Jones's SRPT Position: Q3 2026 in Review

Brighton Jones sold out of Sarepta Therapeutics (SRPT) in Q3 2026, closing a stake of 19,491 shares — an estimated $350K sold.

Brighton Jones first reported a position in SRPT in Q3 2017 and held it in 6 quarters. The position peaked at $718K in Q1 2026. 253 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Brighton Jones reported no remaining Sarepta Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Brighton Jones sold 19,491 Sarepta Therapeutics shares in Q3 2026, an estimated $350K.
  • Brighton Jones first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 6 quarters.
  • Brighton Jones's Sarepta Therapeutics position peaked at $718K in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.